ANI Pharmaceuticals 第三季度的收益超出预期，将股价推高至 61.74 美元，评级为“适度买入”。 ANI Pharmaceuticals beat Q3 earnings expectations, driving stock up to $61.74 with a "Moderate Buy" rating.

ANI制药公司报告说,Q3的收益为每股1.34美元,比预期的1.09美元多,收入为1.483亿美元,比上一年增加12.5%。 ANI Pharmaceuticals reported Q3 earnings of $1.34 per share, beating the expected $1.09, with revenue at $148.30 million, up 12.5% year-over-year. 该公司将2024财政年度EPS指南更新为4900-5.550,星期一存货增加到61.74美元。 The company updated its FY 2024 EPS guidance to 4.900-5.050 and saw its stock rise to $61.74 on Monday. 分析师的“机动购买”评级为77.33美元,目标价格为77.33美元。 Analysts have a "Moderate Buy" rating with a target price of $77.33.